Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,852 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Completed No phase listed Observational

Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01005368
View directory record Official record
Conditions
Leukemia
Interventions
fluorescence in situ hybridization, mutation analysis, nucleic acid sequencing, polymerase chain reaction, western blotting, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
35
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCSD Take Charge Study

NCT01345500
View directory record Official record
Conditions
Overweight, Obese, Obesity, Diabetic, Type 2 Diabetes
Interventions
Higher Carbohydrate, Lower Fat Diet, Lower carbohydrate, Higher fat diet, Individualized Counseling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
La Jolla, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 4 Interventional

Dialysis Clinical Outcomes Revisited (DCOR) Trial

NCT00324571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer hydrochloride, Calcium-based phosphate binder
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
72
States / cities
Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 31, 2026, 7:24 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

NCT01515787
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound
Drug · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1048
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 31, 2026, 7:24 PM EDT
Recruiting Not applicable Interventional

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

NCT06796543
View directory record Official record
Conditions
Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Consolidative radiation therapy (cRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 39 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

NCT00262990
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
EPO906 (Patupilone), doxorubicin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
104
States / cities
Anchorage, Alaska • Flagstaff, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 31, 2026, 7:24 PM EDT
Active, not recruiting Not applicable Interventional

Mobile Health for Adherence in Breast Cancer Patients

NCT06112613
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention
Other · Procedure · Behavioral
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
499
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
View directory record Official record
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Terminated No phase listed Observational

PACMAN Ultrasound Recording Data Collection

NCT03368976
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Not listed
Lead sponsor
Avanos Medical
Other
Eligibility
18 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Gulf Breeze, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

Diuretic Comparison Project

NCT02185417
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
20,723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 31, 2026, 7:24 PM EDT
Recruiting Phase 2 Interventional

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174
View directory record Official record
Conditions
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions
Tovorafenib
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT04052997
View directory record Official record
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Camidanlumab Tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
16 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02165215
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
33
States / cities
Orange, California • San Diego, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 31, 2026, 7:24 PM EDT
Active, not recruiting Not applicable Interventional

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

NCT05686317
View directory record Official record
Conditions
Heart Failure
Interventions
Edwards APTURE transcatheter shunt system, Sham procedure
Device · Diagnostic Test
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

NCT00333840
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
62
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 31, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Recruiting Phase 2 Interventional

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

NCT06712823
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
atumelnant (CRN04894)
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
16 Years to 74 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Minneapolis, Minnesota • Morehead City, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Not applicable Interventional

The Implementation of a Post-operative Communication App to Improve Pain Control and Opioid Use

NCT06124079
View directory record Official record
Conditions
Acute Pain
Interventions
OPY interactive messaging service, Standard care
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Withdrawn Phase 4 Interventional

Celecoxib (Celebrex) in the Management of Acute Renal Colic

NCT00304317
View directory record Official record
Conditions
Ureteral Calculi
Interventions
celecoxib, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Active, not recruiting Not applicable Interventional

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

NCT06216574
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Internet-based Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
236
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 7:24 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 31, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

NCT00610740
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
topical gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 31, 2026, 7:24 PM EDT